This MUST be NHS initiated prescription , if T3 trial was initiated privately , it is still coded as 'Black' ie Prescription not Recommended .
I've been keeping an eye on the LSCMMG Minutes for about a year while they review the codes for New Patients in this area... and finally despite a couple of the CCG's objecting and wanting it to be 'Black' for new patients.. it has been agreed that it will be coded 'Amber 0' (the same as it already is for Existing Patients), and their prescribing guidelines have (finally) been updated to show this clearly.
This means it's now allowed to be prescribed here for NEW patients ... previously Liothyronine was 'Amber' for Existing Patients only, with New Patients being coded as 'Grey' ~ meaning "under review, Prescription Not Recommended"
Lancashire and South Cumbria Medicines Management Group LSCMMG:
NHS Trust Members:
Blackpool Teaching Hospitals NHS Foundation Trust
East Lancashire Hospitals NHS Trust
Lancashire and South Cumbria NHS Foundation Trust
Lancashire Teaching Hospitals NHS Foundation Trust
University Hospitals of Morecambe Bay NHS Foundation Trust
CCG Members:
Blackpool CCG
Blackburn with Darwen CCG
Chorley and South Ribble CCG
East Lancashire CCG
Fylde and Wyre CCG
Greater Preston CCG
Morecambe Bay CCG
West Lancashire CCG
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
"Amber medicines
Amber level 0
Suitable for prescribing in primary care following recommendation or initiation by a specialist.
Little or no specific monitoring required.
Patient may need a regular review, but this would not exceed that required for other medicines routinely prescribed in primary care.
Brief prescribing document or information sheet may be required.
Primary care prescribers must be familiar with the drug to take on prescribing responsibility or must get the required information.
When recommending or handing over care, specialists should ask primary care prescribers to take over prescribing responsibility, and should give enough information about the indication, dose, monitoring requirements, use outside product licence and any necessary dose adjustments to allow them to confidently prescribe."
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
NEW PATIENTS updated 18 -Oct -2022
lancsmmg.nhs.uk/medicines-l...
"Indication:
Add-on treatment for refractory hypothyroidism despite adequate replacement with levothyroxine – new patients.
Background:
*Amber 0 – following successful 3 month trial (to be conducted in secondary care)*
Please note: all other potential causes of symptoms must be excluded. Patients are eligible for a three month trial initially with the option to continue if there is clinical benefit. Patients with a supressed TSH should be referred for a secondary care opinion before continuing liothyronine in primary care
Recommendation:
LSCMMG recommendation: Amber Level 0
Reason for decision: Suitable for GP prescribing following recommendation/initiation by specialist.
Last Updated: 18 - Oct - 2022 "
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
lancsmmg.nhs.uk/medicines-l... (Liothyronine commenced in private Sector ~Black~ Not Recommended)
lancsmmg.nhs.uk/medicines-l... (Liothyronine for resistant depression ~Black ~Not Recommended)
lancsmmg.nhs.uk/medicines-l... (Liothyronine Monotherapy ~Black ~ Not Recommended)
lancsmmg.nhs.uk/medicines-l... (Thyroid Extracts [unlicenced liothyronine and thyroid extract products] ~Black ~Not Recommended)
lancsmmg.nhs.uk/medicines-l... (Liothyronine for Existing patients ~Amber 0 ~ Suitable for GP prescribing following recommendation/initiation by specialist)